First-of-its-Kind inhaled powder vaccine tested for Tough-to-Treat lung cancers
NCT ID NCT06928922
Summary
This is an early-stage study testing the safety of a new type of inhaled vaccine for people with advanced lung cancer or other cancers that have spread to the lungs. The vaccine is a dry powder containing mRNA designed to teach the immune system to attack cancer cells. The study will enroll about 83 patients who have already tried standard treatments without success, to find a safe dose and see if the vaccine shows early signs of helping.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.